| Prev Close | 223.72 |
| Open | 223.49 |
| Day Low/High | 218.25 / 224.28 |
| 52 Wk Low/High | 170.56 / 244.99 |
| Volume | 3.65M |
| Avg Volume | 3.37M |
Amgen Inc. (AMGN)
221.10
2.60
1.20
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 588.25M |
| Market Cap | 133.48B |
| EPS | 13.00 |
| P/E Ratio | 17.77 |
| Div & Yield | 6.40 (2.66%) |
Jim Cramer Previews the Fed Statement and Talks Apple, Oil, Amgen and MSCI
TheStreet's Jim Cramer discusses Wednesday's trending stocks.
Health Care Putting in a Base
Healthcare stocks had a heckuva four-year period of over-performance that ended in the summer of 2015. Since then the Health Care Select Sector SPDR ETF (40% pharma and 15% biotech) has had a series of trading-range moves as sector prices lagged. La...
Egalet Makes Friday's Biotech Mailbag
Why the name is sagging, and what it will take to spur the sector higher.
Cramer: When a Trump Tweet Is a Buy Signal
Drug companies are the latest targets/beneficiaries.
Jim Cramer on Donald Trump's Drug Tweet: "No One Really Knows What He Means"
Jim Cramer says no one really knows what President Trump means when it comes to drug pricing.
Drugmakers Suffer After Trump Tweet
Stocks were under pressure again after Donald Trump made vague promises to lower drug prices.
Amgen Is Making an Important Upside Breakout
The 50-day moving average is crossing the 200-day for a bullish golden cross; go long here.
Amgen Shows a Bullish Breakout
There is more upside to come for this stock.
Health Care ETF Has Been Ailing
You might want to review your holdings in the sector.
Cramer: If You Think I'm Drinking the Kool-Aid, Swallow This
Some tried-and-true indicators show what's really going on with the market.
Streamlined FDA Approval Process Would Boost Drug Makers
Would get drugs to market faster and possibly more cheaply.
Novice Trade: AbbVie
Getting FDA to streamline its approval process would boost drug makers.
There Is So Little Attention Paid to the Fed Meeting
The Fed is simply not a market catalyst this time.
Nike, Disney, Amgen: When Charts, Fundamentals Don't Match
There's not much reason to be bullish on these stocks.
3 Stocks Ripe for a Big Rebound in 2017
Nike, Disney and Amgen shares struggled in 2016. Here is why they are ready to rebound in 2017.
5 Companies That Will Benefit Most From a $500 Billion Tax Holiday
Apple could be the biggest winner if the Trump administration grants U.S. companies a repatriation tax holiday.
Drug Stocks Find Trump Animus a Bitter Pill
The president-elect's words rattled the sector, though Amgen appears to be shrugging off his remarks.
Bullish and Bearish Reversals in the Market
These companies show signs of a change of direction.
5 Stocks Set to Rocket Higher
Looks like these five stocks could rocket higher.
Closing Bell: Active Oil Rigs Rise; Dow Gets Close to 20K but Falls Short
The Dow Jones Industrial Average came agonizingly close to its 20,000 milestone before falling short and backing off.
Jim Cramer Sees Buying Opportunities in Praluent Patent Suit
After a court halts Regeneron's sales of Praluent, Jim Cramer sees opportunity in Amgen.
Prepare for Biotech Action Aplenty Today
As we await the jobs report, there is significant news across the biotech sector in the past 24 hours on some names I have mentioned in these pages. Amgen should be up nicely today after a judge stated that Regeneron would have to pull its PCKS9 inh...
Regeneron Cholesterol-Lowering Drug Banned From U.S. Market
A federal judge has banned the sale of Regeneron's cholesterol-lowering drug Praluent, handing a surprise and overwhelming victory to Amgen and its competing drug Repatha in a long-running patent lawsuit.
Amgen Establishes a Bottom and Signals It's Time to Buy
Traders could buy a dip to $150 if available or they can buy strength above $155, which ever comes first.
My Top Pick for 2017: Short QQQ
Six reasons why the Nasdaq 100 ETF seems ready to pull back.
My Top Pick for 2017: Short QQQ
My trade of the year for 2017 is to short the PowerShares QQQ Trust ETF , which tracks the Nasdaq 100 index. Here's my investment thesis for this play: The Nasdaq 100 Already Has Rallied QQQ already has risen from about $96 a share at the market's F...
Amgen Can Handle Patent Expiration Risks
It's got several newly launched promising drugs, a number of late-stage prospects and strong financials.
Expect Some Big-Cap Biotech Love in 2017
We touched briefly on housing in our first post this morning. There are still some cheap home-building stocks if the housing market continues to improve, which I expect as I believe economic growth will pick up in 2017. I have done well with this se...
